Tuesday, July 15, 2025 – The source discusses research indicating that postmenopausal women on hormone therapy (HT) experience significantly greater weight loss when treated with tirzepatide, an obesity medication, compared to those not on HT. This effect mirrors prior findings…
Sunday, July 13, 2025 – The provided text offers a comprehensive overview of how obesity has been understood and depicted across different historical periods, from ancient civilizations to the present day. It traces the evolution of obesity from being a symbol of wealth or a moral…
Saturday, July 12, 2025 – This document presents a pilot feasibility study published in “Obesity Science & Practice” that investigates the effectiveness of an AI-driven Virtual Human (VH) intervention designed to enhance General Practitioner (GP) obesity education and communication skills. The research highlights the growing global…
Friday, July 11, 2025 – This scholarly article from Aesthetic Surgery Journal Open Forum discusses the phenomenon of “Ozempic Face,” a term used to describe the accelerated facial aging and volume loss experienced by some patients undergoing rapid weight loss from GLP-1 receptor agonists like Ozempic.…
Thursday, July 10, 2025 – There is growing evidence—especially in the plastic surgery community—that the recent surge in GLP‑1 medications (like Ozempic, Wegovy, Mounjaro) for weight loss is fueling a wave of “trim & sculpt” surgeries to address excess skin…
Monday, July 7, 2025 – The provided text, originating from the Food and Drug Administration (FDA), serves as a crucial public health warning regarding counterfeit Ozempic (semaglutide) injections found within the U.S. drug supply chain. It details multiple instances where fake versions of the medication…
Saturday, July 5, 2025 – This original research article examines the real-world effectiveness of semaglutide and tirzepatide for obesity treatment, focusing on how medication discontinuation impacts weight loss and glycemic control. The retrospective cohort study analyzed electronic health records from a large patient population in Ohio and Florida. It reveals…
Monday, June 30, 2025 – We ask experts for their views on the GLP-1 market in this exclusive eBook. GLP-1 receptor agonists have rapidly evolved from niche diabetes drugs to headline-grabbing agents of a global weight-loss revolution. But the science,…
Monday, June 30, 2025 – Your Weight Matters Regional is traveling the country, bringing expert-led education and practical guidance to cities near you. These FREE half-day events are designed to meet you wherever you are in your journey—whether you’re just…
Tuesday, June 24, 2025 – This document details a Phase 3a, 68-week, multicenter, double-blind, placebo-controlled, and active-controlled clinical trial (REDEFINE 1) investigating the efficacy and safety of cagrilintide–semaglutide (CagriSema) for weight loss in adults who are overweight or obese. The study randomized over 3400 participants into…